These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36443599)

  • 1. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.
    Karlström P; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction.
    She J; Lou B; Liu H; Zhou B; Jiang GT; Luo Y; Wu H; Wang C; Yuan Z
    ESC Heart Fail; 2021 Dec; 8(6):4607-4616. PubMed ID: 34664407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
    Houchen E; Loefroth E; Schlienger R; Proudfoot C; Corda S; Saha S; Satwase SK; Studer R
    Cardiol Ther; 2022 Mar; 11(1):113-127. PubMed ID: 35094306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
    Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
    D'Amario D; Rodolico D; Rosano GMC; Dahlström U; Crea F; Lund LH; Savarese G
    Eur J Heart Fail; 2022 May; 24(5):871-884. PubMed ID: 35257446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
    Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
    ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.
    Park DY; An S; Attanasio S; Jolly N; Malhotra S; Doukky R; Samsky MD; Sen S; Ahmad T; Nanna MG; Vij A
    Am J Cardiol; 2023 Jan; 187():84-92. PubMed ID: 36459752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.
    Bhat TS; Hafeez I; Tak SF; Mattoo A; Patigaroo AR; Khan A; Lone AA; Beig JR
    Indian Heart J; 2022; 74(3):178-181. PubMed ID: 35483448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
    Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.